GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Analyst Ratings Changes
Several research analysts have weighed in on the company. Credit Suisse Group upped their target price on GSK from GBX 1,400 ($16.92) to GBX 1,600 ($19.33) in a research report on Friday, July 15th. Barclays upped their target price on GSK from GBX 1,775 ($21.45) to GBX 1,800 ($21.75) in a research report on Friday, April 29th. StockNews.com assumed coverage on GSK in a research report on Thursday, July 28th. They issued a "strong-buy" rating on the stock. TheStreet raised GSK from a "c+" rating to an "a-" rating in a research report on Friday, July 22nd. Finally, Citigroup reissued a "neutral" rating on shares of GSK in a report on Thursday, July 21st. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, one has given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $1,787.50.
GSK Stock Performance
Shares of NYSE:GSK opened at $35.73 on Friday. The business's 50-day simple moving average is $42.29 and its 200-day simple moving average is $43.34. GSK has a 52 week low of $34.50 and a 52 week high of $46.97. The firm has a market cap of $72.66 billion, a price-to-earnings ratio of 11.83, a P/E/G ratio of 1.43 and a beta of 0.46. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.31 and a current ratio of 1.43.
GSK Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 6th. Investors of record on Friday, August 19th will be paid a dividend of $0.383 per share. This is an increase from GSK's previous quarterly dividend of $0.35. The ex-dividend date is Thursday, August 18th. This represents a $1.53 annualized dividend and a yield of 4.29%. GSK's dividend payout ratio is presently 55.30%.